ERBB2 and non-small cell lung carcinoma: Although a compact NGS panel, which tests for key alterations, has become standard of care in certain entities, such as non-resectable non-small cell lung cancer (NSCLC), initial molecular testing in mCRC is typically restricted to RAS, BRAF, and MSI status, despite some recently released guidelines recommending ERBB2 testing [27,28].